The effects of deanol on cognitive performance and electrophysiology in elderly humans
β Scribed by Gail R. Marsh; Markku Linnoila
- Publisher
- Springer
- Year
- 1979
- Tongue
- English
- Weight
- 583 KB
- Volume
- 66
- Category
- Article
- ISSN
- 0033-3158
No coin nor oath required. For personal study only.
β¦ Synopsis
Deanol (900 mg/day for 21 days) had no effect on learning a list of words when tested at weekly intervals. Tests of simple and complex reaction time and a test of continuous serial decoding of digits showed no enhancement with the drug. Several components of evoked potentials recorded from several scalp sites did show enhanced amplitude under drug treatment. These changes were not accompanied by changes in the EEG spectrum as are seen with some other psychoactive drugs. Deanol seems to be an ineffective treatment for the normal slowing of cognitive function seen in the normal elderly person or those elderly with only minimal cognitive decline and free of symptoms of dementia. Contrary to earlier reports, elderly persons were found to be able to benefit from warning signals in a complex reaction time task.
π SIMILAR VOLUMES
The effects of moclobemide, a new selective and reversible MAO-A inhibitor, on cognitive function and psychomotor performance were measured in 12 healthy elderly male volunteers (with a mean age of 72.5 years). Subjects received moclobemide 200 mg, amitriptyline (positive internal control) 25 mg or
## Abstract ## Background There have been few general population studies of the effects of psychotropic treatment on cognitive functioning in the elderly. Current evidence based on studies with numerous procedural shortenings supports the notion of the detrimental effect. ## Objectives To examin
## Abstract ## Background Electroconvulsive therapy (ECT) as a single course or in maintenance form (MβECT) is an effective treatment in depressed elderly. However, ECT may have adverse effects on cognition. ## Objective To review all studies from 1980β2006 on ECT and cognition in the elderly wi
Twenty residents with mild to moderate memory impairment probably due to senile dementia of Alzheimer type entered a placebo-controlled, double-blind, crossover trial of meclofenoxate 600 mg administered twice daily for 12 weeks. Nine subjects completed the trial during which various tests of cognit
Clinical recovery, cognitive function, and ward behavior indicative of organic brain syndrome were assessed in 12 elderly, depressed patients before, and approximately one week after, treatment with electroconvulsive therapy (ECT). There was a statistically significant improvement in depression, and